ARIXTRA

Product Overview

About ARIXTRA

ARIXTRA is a prescription medication containing the active ingredient Fondaparinux Sodium, a synthetic anticoagulant that mimics the antithrombin III-mediated inhibition of Factor Xa. It is used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopedic surgery of the hip or knee.

Key Benefits & Uses

• Prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopedic surgery of the hip or knee.
• Reduction of the risk of DVT and PE in patients undergoing major orthopedic surgery of the hip or knee.
• Prevention of postoperative DVT and PE in patients undergoing major orthopedic surgery of the hip or knee.

Active Ingredient & Action

Fondaparinux Sodium, the active ingredient in ARIXTRA, works by selectively binding to antithrombin III, thereby inhibiting the coagulation factor Xa. This results in the prevention of thrombin formation and subsequent clot formation. Fondaparinux Sodium has a predictable and stable anticoagulant response, making it an effective treatment for preventing DVT and PE in patients undergoing major orthopedic surgery.

Important Notes

ARIXTRA is available in a single dose of 2.5 mg or 5 mg. It is administered subcutaneously once daily for a duration of 5 to 9 days, depending on the patient's risk factors and surgical procedure. Patients with renal impairment or those taking other anticoagulants should be closely monitored for signs of bleeding or thrombocytopenia. It is essential to follow the recommended dosage and administration instructions to minimize the risk of adverse effects.